Current indications and future perspective of fluorescence bronchoscopy: A review study

Summary 

Background

Autofluorescence bronchoscopy (AFB) was introduced into clinical practice early in the 1990s for identification and localisation of intra-epithelial pre-neoplastic (dysplastic mucosa) and early neoplastic (carcinoma in situ) endobronchial lesions.

Objectives

to determine the current range of indications of AFB through review of published literature and to compare sensitivity and specificity of AFB with those of WLB for identification of pre- and early neoplastic lesions in each of the indications.

Method

Search of the literature produced 62 eligible articles for the review. These were “empirically” classified into five categories:

Results

In all categories the sensitivity of AFB was several times greater than WLB in identifying pre-neoplastic and early neoplastic lesions and the specificity of WLB was higher than that of AFB. When AFB was used for identification and localisation of dysplasia and carcinoma in situ its sensitivity was 25–47% (mean 33%) higher than that of WLB. Its specificity was 7–18% (mean 11%) lower than WLB.

The ratio of sensitivity of AFB/WLB was highest in every category when the population tested comprised a higher proportion of pre- and early neoplastic lesions than invasive cancer. In such cases there was relatively lower specificity for AFB compared to WLB.

Conclusion

The review suggests that AFB should be included in routine investigations of patients suspected of having lung cancer, those undergoing lung cancer surgery and in post-treatment follow-up to discover early cancer and/or recurrence. Also, it has to be included in any screening programme protocol.

Keywords: Autofluorescence bronchoscopy indications, Autofluorescence and white light bronchoscopy